SAVA (Cassava Sciences) ROE % Adjusted to Book Value : -7.42% (As of Sep. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Cassava Sciences ROE % Adjusted to Book Value?

Cassava Sciences's ROE % for the quarter that ended in Sep. 2024 was -62.86%. Cassava Sciences's PB Ratio for the quarter that ended in Sep. 2024 was 8.47. Cassava Sciences's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -7.42%.

Cassava Sciences ROE % Adjusted to Book Value Historical Data

The historical data trend for Cassava Sciences's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cassava Sciences ROE % Adjusted to Book Value Chart

Cassava Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-4.32

-4.25

-2.72

-5.84

-7.70

Cassava Sciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-13.57	-8.27	8.30	5.86	-7.42

Competitive Comparison of Cassava Sciences's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Cassava Sciences's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cassava Sciences's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cassava Sciences's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Cassava Sciences's ROE % Adjusted to Book Value falls into.

Cassava Sciences ROE % Adjusted to Book Value Calculation

Cassava Sciences's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-53.27%	/	6.92
	=	-7.70%

Cassava Sciences's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-62.86%	/	8.47
	=	-7.42%

Cassava Sciences ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Cassava Sciences's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Cassava Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cassava Sciences Inc (NAS:SAVA) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

SAVA:Mexico PX91:Germany PX91:Germany

Address

6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731

Website

https://www.cassavasciences.com

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.

Executives

James William Kupiec	officer: Chief Clinical Dev. Officer	7801 N CAPITAL OF TEXAS HIGHWAY, SUITE 260, AUSTIN TX 78731
Eric Schoen	officer: Chief Financial Officer	7801 N. CAPITAL OF TX HWY, SUITE 260, AUSTIN TX 78731
Sanford Robertson	director	ONE LETTERMAN DRIVE, BUILDING C SUITE 410, SAN FRANCISCO CA 94129
Richard Barry	director	285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Robert Christopher Cook	officer: SVP & General Counsel	6801 N. CAPITAL OF TEXAS HWY, BUILDING 1, SUITE 300, AUSTIN TX 78731
Remi Barbier	director, 10 percent owner, officer: CEO, Chairman of the Board
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
O Donnell Michael J	director
Robert Z Gussin	director
Scannon Patrick J Md Phd	director	C/O XOMA, LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
Saira Ramasastry	director	501 CANAL BLVD., RICHMOND CA 94804
Nadav Friedmann	director, officer: Chief Scientific Officer
Sabretooth Master Fund, L.p.	10 percent owner	405 LEXINGTON AVENUE, 50TH FLOOR, NEW YORK NY 10174